Increased epidermal growth factor receptor in fsn/fsn mice

Journal of Investigative Dermatology

Volumn 106, Issue 6, 1996, Pages 1169-1174

  Nanney, Lillian B ^a,b,d   Sundberg, John P ^c   King, Lloyd E ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c JACKSON LABORATORY   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cyclosporin A; flaky skin; Koebner reaction; psoriasis model; UVB

Indexed keywords

CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; ULTRAVIOLET B RADIATION;

EID: 0029884718     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12347791     Document Type: Article

References (34)

1. Amsellem C, Haftek M, Thivolet J, De Doncker P, Schmitt D: Potentializing effect of ketoconazole on cyclosporin A-induced inhibition of keratinocyte DNA synthesis. Acta Derm Venereol (Stockh) 74:257-259, 1994
2. Christophen E, Mrowietz U, Henneicke H-H, Farber L, Welzel D: Cyclosporine in psoriasis. A multicenter dose finding study in severe plaque psoriasis. J Am Acad Dermatol 26:86-90, 1992
3. Dominey AM, Wang X-J, King LE, Nanney LB, Gagne TA, Sellheyer C, Bundman DS, Longley MA, Rothnagel JA, Greenhalgh DA, Roop D: Targeted over expression of transforming growth factor-α in the epidermis of transgenic mice elicits anomalous proliferation and differentiation and spontaneous squamous papillomas. Cell Growth Differ 4:1071-1082, 1993
4. Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ, Ellingsworth L, Derynck R, Voorhees JJ: Overexpression of transforming growth factor-α in psoriatic epidermis. J Invest Dermatol 243:811-814, 1989
5. Elder JT, Hammerberg C, Cooper KD, Kojima T, Nair RP, Ellis CN, Voorhees JJ: Cyclosporin A rapidly inhibits epidermal cytokine expression of psoriasis lesions, but not in cytokine-stimulated cultured keratinocytes. J Invest Dermatol 101:761-766, 1993
6. Ellis CN, Gorsulowsky DC, Hamilton TA: Cyclosporine improves psoriasis in a double-blind study. JAMA 256:3110-3116 1986
7. Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP: Detection of transforming growth factor α in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med 167:670-675, 1988
8. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1:442-447, 1995
9. Higashiyama M, Hashimoto K, Matsumoto K, Yoshikawa K: Differential expression of TGFα and EGF receptor in the transitional area ot psoriatic epidermis. J Dermatol Sci 7:45-53, 1994
10. HoganEsch J, Gijlels MJJ, Offerman E, Hooft JV, Bekkum DWV. Zurcher C: A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol 143:972-982, 1993
11. Kane CB, Knapp AM, Mansbridge JN, Hanawalt PC: Transforming growth factor-betal localization in normal and psoriatic epidermal keratinocytes in situ. J Cell Physiol 144:144-150, 1990
12. Krane JF, Murphy DP, Carter DM, Krueger JG: Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor 1/somatomedin C (IGF-1) on keratinocyte proliferation may be mediated by IGF-1 transmodulation of the EGF receptor. J Invest Dermatol 96:419-424, 1991a
13. Krane JF, Murphy DP, Gottlieb AB, Carter DM, Hart CE, Krueger JG: Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. J Invest Dermatol 96:983-986, 1991b
14. Krueger GG, Manning DD, Malouf J, Ogden B: Long term maintenance of psoriatic human skin on congenitally athymic (nude) mice. J Invest Dermatol 64:307-312, 1975
15. Laburte C, Grossman K, Abi-Rached J, Abeywickrama KH, Dubertret L: Efficacy and safety of oral cyclosporin A (CyA: Sandimmune) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 130:366-375, 1992
16. Massague J: Transforming growth factor-β modulates the high affinity receptors for epidermal growth factor and transforming growth factor alpha. J Cell Biol 1011:1500-1514, 1995
17. Morita K, Hogan MH, Nanney LB, King LE, Monabe M, Sun T-T, Sundberg JP: Cutaneous ultrastructural features of the flaky skin (fsn/fsn) mouse mutation. J Dermatol 22:385-395, 1995
18. Nanney LB: Epidermal and dermal effects of epidermal growth factor during wound repair. J Invest Dermatol 94:624-629, 1990
19. Nanney LU, Gates RE, Todderud G, King LE, Carpenter G: Altered distribution of phospholipase Cγ1 in benign hyperproliferative skin diseases. Cell Growth Differ 3:233-239, 1992a
20. Nanney LB, Magid M, Stoscheck CM, King LE: Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 83:385-393, 1984
21. 125I] epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 86:260-265, 1986
22. Nanney LB, Yates RA, King LE: Modulation of epidermal growth factor receptors in psoriatic lesions during treatment with topical EGF. J Invest Dermatol 98:296-301, 1992b
23. Nickoloff BJ: Cytokine network in psoriasis. Arch Dermatol 127:871-884, 1991
24. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM: Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 146:580-599, 1995
25. Sibilia M, Wagner EF: Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269:234-238, 1995
26. Stoscheck CM, Nanney LB, King LE: Quantitative determination of EGF-R during epidermal wound healing. J Invest Dermatol 99:645-649, 1992
27. Sundberg JP, Boggess D, Schultz LD, Beamer WG: The flaky skin (fsn) mutation, chromosome ?. In: Sundberg JP (ed.), Handbook of Mouse Mutations Wth Skin and Hair Abnormalities: Animal Models and Biochemicals Tools. CRC Press, Boca Raton, FL 1994a, pp 253-268
28. Sundberg JP, Boggess D, Sundberg BA, Beamer WG, Shultz LD: Epidermal dendritic cell populations in the flaky skin mutant mouse. Immunol Invest 22:389-401, 1993
29. Sundberg JP, Dunstan RW, Roop DR, Beamer WG: Full-thickness skin grafts from flaky skin mice to nude mice: maintenance of the psoriasiform phenotype. J Invest Dermatol 102:781-788, 1994b
30. Sundberg JP, HogenEsch H, King LE: Mouse models for scaly skin diseases. In: Maibach H (ed.). Models for Dermatology Research. CRC Press, Boca Raton, FL, 1995
31. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, Coffey RJ, Magnuson T: Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269:230-234, 1995
32. Turbitt ML, Akhurst RJ, White SI, MacKie RM: Localization of elevated transforming growth factor-α in psoriatic epidermis. J Invest Dermatol 95:383-387, 1990
33. Watts P, Stables GS, Akhurst RJ, Mackie RM: Localization of transforming growth factor-alpha RNA and protein in the skin of psoriatic patients receiving therapy. Br J Dermatol 131:64-71, 1994
34. Won YH, Sauder DN, McKenzie RC: Cyclosporin A inhibits keratinocyte cytokine gene expression. Br J Dermatol 130:312-319, 1994